{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T16:22:48Z","timestamp":1782750168412,"version":"3.54.5"},"reference-count":20,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T00:00:00Z","timestamp":1429660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:p>Pemetrexed (Alimta\u00ae) is a novel anti-folate antimetabolite agent that is used in combination with cisplatin for the treatment of patients with unresectable malignant pleural mesothelioma and as a single agent or in combination with cisplatin for patients with locally advanced or metastatic non-small-cell-lung-cancer. Cutaneous adverse reactions are common side effects of pemetrexed for which the manufacturer recommends 3-day premedication with dexamethasone 4\u2009mg by mouth twice daily\u2014(the day before, the day of, and the day after treatment). Patients\u2019 adherence to this premedication regimen is of concern. We report 14 cases of metastatic non-small-cell-lung-cancer patients who were premedicated with a single dose of dexamethasone 20\u2009mg prior to pemetrexed or pemetrexed-based chemotherapy. None of these patients reported a grade 3 or above skin reactions over the course of their treatments. These findings suggest that a single dose of dexamethasone 20\u2009mg may be an alternative premedication regimen in patients with metastatic non small cell lung cancer receiving pemetrexed or pemetrexed-based chemotherapy.<\/jats:p>","DOI":"10.1177\/1078155215583523","type":"journal-article","created":{"date-parts":[[2015,4,23]],"date-time":"2015-04-23T20:11:35Z","timestamp":1429819895000},"page":"271-274","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions"],"prefix":"10.1177","volume":"22","author":[{"given":"Raymond","family":"Elsoueidi","sequence":"first","affiliation":[{"name":"Department of Medicine, Appalachian Regional Healthcare Cancer Center, Hazard, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Lander","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie M","family":"Richa","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyob D","family":"Adane","sequence":"additional","affiliation":[{"name":"Department of Pharmacy practice, Raabe College of Pharmacy, Ohio Northern University, Ada, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,4,22]]},"reference":[{"key":"bibr1-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-040010"},{"key":"bibr2-1078155215583523","volume-title":"(Pemetrexed) package insert","author":"Eli Lilly and Company","year":"2013"},{"key":"bibr3-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.163"},{"key":"bibr4-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"bibr5-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"bibr6-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1194"},{"key":"bibr7-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-6-363"},{"key":"bibr8-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3009"},{"key":"bibr9-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008305205159"},{"key":"bibr10-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf115"},{"key":"bibr11-1078155215583523","first-page":"769","volume":"2","author":"Pierard-Franchimont C","year":"2011","journal-title":"Oncol Lett"},{"key":"bibr12-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.11.2842"},{"key":"bibr13-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5143"},{"key":"bibr14-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61497-5"},{"key":"bibr15-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0375"},{"key":"bibr16-1078155215583523","first-page":"75","volume":"40","author":"Ishikawa H","year":"2013","journal-title":"Gan To Kagaku Ryoho"},{"key":"bibr17-1078155215583523","doi-asserted-by":"crossref","unstructured":"Coscio A. Phase I study of pemetrexed in recurrent\/metastatic head and neck squamous cell cancer (HNSCC) and to assess the need for steroid premedication. In:\n                      2009 ASCO annual meeting proceedings (post-meeting edition)\n                      , Chicago, USA, 29 May to 2 June 2009, abstract no 15S, pp. e17009. Chicago: ASCO.","DOI":"10.1200\/jco.2009.27.15_suppl.e17009"},{"key":"bibr18-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6546"},{"key":"bibr19-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210367950"},{"key":"bibr20-1078155215583523","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-25-3-343"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215583523","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155215583523","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215583523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:14Z","timestamp":1777688174000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155215583523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,22]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1177\/1078155215583523"],"URL":"https:\/\/doi.org\/10.1177\/1078155215583523","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,22]]}}}